Does Parkinson's Disease Increase the Risk of Developing Diabetes?
No, Parkinson's disease does not increase the risk of developing diabetes; in fact, the relationship appears to be reversed—diabetes increases the risk of developing Parkinson's disease, not the other way around.
The Directional Relationship
The evidence consistently demonstrates that diabetes mellitus acts as a risk factor for Parkinson's disease, rather than PD predisposing to diabetes 1, 2, 3. This is a critical distinction that reverses the premise of your question.
Key Evidence on Diabetes → Parkinson's Direction
Diabetes significantly increases PD risk and accelerates disease progression, affecting both motor and cognitive functions through shared pathophysiological mechanisms including insulin resistance, oxidative stress, mitochondrial dysfunction, and chronic neuroinflammation 1
In patients with established PD who also have diabetes, the presence of diabetes is associated with more aggressive disease phenotype, including faster motor progression (HR = 4.521) and cognitive decline (HR = 9.314) over 36 months 2
Diabetes in PD patients correlates with higher motor scores, lower striatal dopamine transporter binding, and elevated tau CSF levels 2
Evidence on Parkinson's → Diabetes Direction (Limited Risk)
The most recent and highest-quality study directly addressing your question found that the risk of developing diabetes after PD diagnosis is relatively low 4:
- Only 8.4% of incident PD patients (666 out of 7,976) developed type 2 diabetes during a mean follow-up of 7.1 years
- Male PD patients had significantly reduced risk of developing diabetes (HR = 0.77; 95% CI: 0.66-0.89) compared to females
- Interestingly, PD patients who developed uncomplicated diabetes had lower mortality risk (HR = 0.70; 95% CI: 0.62-0.78) than those without diabetes
Mechanistic Considerations
The bidirectional relationship exists through overlapping pathways 5:
- Insulin resistance and impaired insulin signaling
- Oxidative stress and mitochondrial dysfunction
- Chronic inflammation and neuroinflammation
- Dysregulated glucose metabolism
However, the dominant clinical direction is diabetes predisposing to PD, not PD causing diabetes 1, 3.
Clinical Implications
Drug Interactions to Monitor
Levodopa may induce metabolic effects including reduced muscle glucose uptake, potentially inducing glucose intolerance, and causing increased plasma glucose and insulin hypersecretion with long-term use 6
Dopaminergic medications used in PD management may alter glucose uptake and exacerbate insulin resistance 5
Potential Protective Strategies
If a PD patient is at risk for diabetes, certain antidiabetic agents may offer neuroprotective benefits:
- GLP-1 receptor agonists and SGLT2 inhibitors show consistently lower ranking probabilities for PD risk compared to older agents like metformin and sulfonylureas 3
Common Pitfalls
- Do not assume PD causes diabetes—the evidence shows minimal increased risk
- Be aware that levodopa treatment may affect glucose metabolism, but this is a medication effect, not a disease effect
- Sex differences matter: male PD patients have lower diabetes risk than females 4